Regen Biopharma Stock Probability of Future Pink Sheet Price Finishing Over 36.07
| RGBP Stock | USD 0.06 0 1.64% |
Regen |
Regen BioPharma Target Price Odds to finish over 36.07
The tendency of Regen Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 36.07 or more in 90 days |
| 0.06 | 90 days | 36.07 | close to zero percent |
Based on a normal probability distribution, the odds of Regen BioPharma to move over $ 36.07 or more in 90 days from now is close to zero percent (This Regen BioPharma probability density function shows the probability of Regen Pink Sheet to fall within a particular range of prices over 90 days) . Probability of Regen BioPharma price to stay between its current price of $ 0.06 and $ 36.07 at the end of the 90-day period is about 88.51 .
Given the investment horizon of 90 days the pink sheet has the beta coefficient of 3.62 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Regen BioPharma will likely underperform. In addition to that Regen BioPharma has an alpha of 3.5752, implying that it can generate a 3.58 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Regen BioPharma Price Density |
| Price |
Predictive Modules for Regen BioPharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Regen BioPharma. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Regen BioPharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Regen BioPharma is not an exception. The market had few large corrections towards the Regen BioPharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Regen BioPharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Regen BioPharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 3.58 | |
β | Beta against Dow Jones | 3.62 | |
σ | Overall volatility | 0.06 | |
Ir | Information ratio | 0.11 |
Regen BioPharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Regen BioPharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Regen BioPharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Regen BioPharma is way too risky over 90 days horizon | |
| Regen BioPharma has some characteristics of a very speculative penny stock | |
| Regen BioPharma appears to be risky and price may revert if volatility continues | |
| Regen BioPharma has high likelihood to experience some financial distress in the next 2 years | |
| Regen BioPharma currently holds 1.58 M in liabilities with Debt to Equity (D/E) ratio of 1.25, which is about average as compared to similar companies. Regen BioPharma has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Regen BioPharma until it has trouble settling it off, either with new capital or with free cash flow. So, Regen BioPharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Regen BioPharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Regen to invest in growth at high rates of return. When we think about Regen BioPharma's use of debt, we should always consider it together with cash and equity. | |
| Regen BioPharma currently holds about 110.99 K in cash with (606.92 K) of positive cash flow from operations. |
Regen BioPharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Regen Pink Sheet often depends not only on the future outlook of the current and potential Regen BioPharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Regen BioPharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 3 B | |
| Cash And Short Term Investments | 51.2 K |
Regen BioPharma Technical Analysis
Regen BioPharma's future price can be derived by breaking down and analyzing its technical indicators over time. Regen Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Regen BioPharma. In general, you should focus on analyzing Regen Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Regen BioPharma Predictive Forecast Models
Regen BioPharma's time-series forecasting models is one of many Regen BioPharma's pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Regen BioPharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Regen BioPharma
Checking the ongoing alerts about Regen BioPharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Regen BioPharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Regen BioPharma is way too risky over 90 days horizon | |
| Regen BioPharma has some characteristics of a very speculative penny stock | |
| Regen BioPharma appears to be risky and price may revert if volatility continues | |
| Regen BioPharma has high likelihood to experience some financial distress in the next 2 years | |
| Regen BioPharma currently holds 1.58 M in liabilities with Debt to Equity (D/E) ratio of 1.25, which is about average as compared to similar companies. Regen BioPharma has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Regen BioPharma until it has trouble settling it off, either with new capital or with free cash flow. So, Regen BioPharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Regen BioPharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Regen to invest in growth at high rates of return. When we think about Regen BioPharma's use of debt, we should always consider it together with cash and equity. | |
| Regen BioPharma currently holds about 110.99 K in cash with (606.92 K) of positive cash flow from operations. |
Additional Tools for Regen Pink Sheet Analysis
When running Regen BioPharma's price analysis, check to measure Regen BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regen BioPharma is operating at the current time. Most of Regen BioPharma's value examination focuses on studying past and present price action to predict the probability of Regen BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regen BioPharma's price. Additionally, you may evaluate how the addition of Regen BioPharma to your portfolios can decrease your overall portfolio volatility.